登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688136 证券简称：科兴制药 公告编号：2025-055 科兴生物制药股份有限公司 股东询价转让定价情况提示性公告 深圳科益医药控股有限公司保证向科兴生物制药股份有限公司（以下简称"公司"）提供的信息内容不存 在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 根据2025年7月31日询价申购情况，初步确定的本次询价转让价格为36.70元/股。 ● 受让方通过询价转让受让的股份，在受让后6个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为36.70元/股。 （二）参与本次询价转让报价的机构投资者家数为14家，涵盖了基金管理公司、合格境外机构投资者、 证券公司、保险公司、私募基金管理人等专业机构投资者。参与本次询价转让报价的机构投资者合计有 效认购股份数量为7,050,000股，对应的有效认购倍数为1.17倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为13家机构投资者 ...

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant growth phase, with expectations for a "1-10" explosive stage as more innovative drugs are launched domestically and representative new drugs appear in overseas markets [1][3] - Innovative drug ETFs have shown strong performance, with several funds achieving over 100% returns this year, indicating a robust interest in this sector [1][2] - The investment landscape is shifting from defensive to offensive strategies, with innovative drugs being viewed as a growth line that can withstand market cycles [3][4] Group 2 - Fund managers express optimism about the potential for excess returns in the innovative drug sector, anticipating a long harvest period starting from 2025 [3][4] - The innovative drug sector is characterized by high investment, long cycles, and intense competition, which may lead to valuation bubbles if not carefully managed [5][6] - Evaluating innovative drug companies should focus on global competitiveness and domestic commercialization capabilities, with an emphasis on strategic partnerships and market positioning [7]

证券代码：688136 证券简称：科兴制药 公告编号：2025-055 科兴生物制药股份有限公司 深圳科益医药控股有限公司保证向科兴生物制药股份有限公司（以下简称 "公司"）提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ? 根据 2025 年 7 月 31 日询价申购情况，初步确定的本次询价转让价格为 ? 受让方通过询价转让受让的股份，在受让后 6 个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 36.70 元/股。 （二）参与本次询价转让报价的机构投资者家数为 14 家，涵盖了基金管理 公司、合格境外机构投资者、证券公司、保险公司、私募基金管理人等专业机构 投资者。参与本次询价转让报价的机构投资者合计有效认购股份数量为 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为 13 家机 构投资者，拟受让股份总数为 6,037,717 股。 二、风险提示 （一）本次询价转让受让方及受让股数仅为初步结果，尚存在拟转让股 ...

Group 1: Clinical Trials and Approvals - Heng Rui Medicine received clinical trial approval for HRS-5041 tablets for prostate cancer treatment, a novel AR-PROTAC small molecule with potential to overcome resistance compared to second-generation AR inhibitors [1] - Microchip Biotech's CS231295 tablets received FDA approval for a Phase I clinical trial targeting advanced solid tumors, noted for its ability to penetrate the blood-brain barrier [2] - Shuyuan obtained a summary report for BDB-001 injection, showing significant clinical advantages in reducing hormone dosage for ANCA-associated vasculitis, with plans to advance to Phase III trials [5] - Huayi Pharmaceutical's HSK3486 received FDA application acceptance for marketing [12] Group 2: Financial Performance - Daodaoquan reported a 563.15% increase in net profit for the first half of 2025, with revenue of 2.792 billion yuan, driven by improved sales and reduced raw material costs [4] - China Petroleum and Chemical Corporation (Sinopec) expects a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, reflecting a decline due to falling oil prices and market competition [6] Group 3: Shareholder Actions - Wanhua Chemical's major shareholder plans to reduce its stake by up to 0.54%, equating to no more than 17 million shares, due to personal financial needs [2] - Ding Tong Technology's controlling shareholder intends to transfer 3% of the company's shares, totaling 417.6 million shares, for similar financial reasons [7] Group 4: New Projects and Investments - Guo En Co., Ltd. announced a project to establish a new platform for PEEK and polystyrene engineering materials with an investment of 960 million yuan, enhancing competitiveness in specialty engineering plastics [8] - Shanying International plans to establish a partnership with a valuation of 2.977 billion yuan to attract long-term investors, including state-owned capital [8]

Group 1: Artificial Intelligence Initiatives - The State Council approved the "Artificial Intelligence +" action plan to promote large-scale commercial applications of AI, leveraging China's complete industrial system and large market scale [1] - The National Development and Reform Commission emphasized the need to deepen the "Artificial Intelligence +" initiative and promote high-quality development of the low-altitude economy [2] - The National Medical Insurance Administration supports the clinical application and pricing of new technologies like brain-computer interfaces, establishing pricing for related medical services [2] Group 2: Corporate Developments - Tesla expanded its Robotaxi service to the California Bay Area, covering cities from San Francisco to San Jose [4] - Dongxin Co. clarified that its products are not used in large model computing clusters, indicating potential risks due to rapid stock price increases [5] - Dingtong Technology's major shareholder plans to transfer 3% of the company's shares due to personal funding needs [5] Group 3: Clinical Trials and Approvals - Yahui Pharmaceutical reported positive preliminary results from its Phase Ib clinical trial for APL-1401, aimed at treating moderate to severe ulcerative colitis [5] - Micron Biotech received FDA approval for a Phase I clinical trial of CS231295, a selective AuroraB inhibitor for treating advanced solid tumors [6] - ST Norate obtained drug registration certificates for two new products, indicating expansion in reproductive and mental health sectors [7] Group 4: Financing and Investments - "Zero Degree Robotics" completed two rounds of financing totaling over 100 million yuan, focusing on technology development and production acceleration [10] - Puliyan Medical completed nearly $50 million in Series C financing to enhance product development and market expansion [11]

证券代码：688136 证券简称：科兴制药 公告编号：2025-055 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 36.70 元/股。 （二）参与本次询价转让报价的机构投资者家数为 14 家，涵盖了基金管理 公司、合格境外机构投资者、证券公司、保险公司、私募基金管理人等专业机构 投资者。参与本次询价转让报价的机构投资者合计有效认购股份数量为 7,050,000 股，对应的有效认购倍数为 1.17 倍。 科兴生物制药股份有限公司 股东询价转让定价情况提示性公告 深圳科益医药控股有限公司保证向科兴生物制药股份有限公司（以下简称 "公司"）提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 7 月 31 日询价申购情况，初步确定的本次询价转让价格为 36.70 元/股。 受让方通过询价转让受让的股份，在受让后 6 个月内不得转让。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为 13 家机 构投资者，拟受让股份总 ...

格隆汇7月31日丨科兴制药(688136.SH)公布，经向机构投资者询价后，初步确定的转让价格为36.70元/ 股。本次询价转让拟转让股份已获全额认购，初步确定受让方为13家机构投资者，拟受让股份总数为 6,037,717股。 ...

证券之星消息，7月31日生物制品板块较上一交易日上涨0.05%，安科生物领涨。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300009 | 安科生物 | 12.11 | 20.02% | 330.56万 | | 38.34亿 | | 688136 | 科兴制药 | 53.25 | 13.15% | 19.24万 | | 9.56亿 | | 688278 | 特宝生物 | 91.33 | 7.46% | 12.10万 | | 11.04亿 | | 300841 | 康华生物 | 77.47 | 5.76% | 11.37万 | | 8.67亿 | | 688293 | 奥浦迈 | 60.50 | 5.38% | 2.60万 | | 1.58亿 | | 301393 | 吴帆生物 | 61.69 | 4.86% | 7.17万 | | 4.37亿 | ...

中国经济网北京7月31日讯 科兴制药（688136.SH）昨晚发布股东询价转让计划书。 2020年12月14日，科兴制药在上交所科创板上市，发行股票数量为4967.53万股，发行价格为22.33元/ 股，保荐机构（主承销商）为中信建投证券，保荐代表人为徐新岳、张星明。 科兴制药首次公开发行股票募集资金总额为11.09亿元，实际募集资金净额为9.95亿元。科兴制药实际募 资净额比原拟募资额少7.10亿元。科兴制药于2020年12月7日披露的招股说明书显示，该公司原拟募资 17.05亿元，拟分别用于药物生产基地改扩建项目、研发中心升级建设项目、信息管理系统升级建设项 目和补充流动资金。 科兴制药首次公开发行股票的发行费用（含税）总额为1.15亿元，其中，保荐及承销费用9385.58万元。 天眼查APP显示，科兴生物制药股份有限公司(曾用名：山东科兴生物制品有限公司)，成立于1997年， 位于山东省济南市，是一家以从事医药制造业为主的企业。企业注册资本19964.225万人民币。 本次拟参与科兴制药首发前股东询价转让（以下简称"本次询价转让"）的股东为深圳科益医药控股有限 公司。出让方拟转让股份的总数为6,037, ...

Core Insights - The company has successfully commercialized its biosimilar product Bevacizumab in multiple countries, including recent approvals in Nigeria, Pakistan, and Colombia, indicating a strong momentum in overseas market expansion [2][3][4] - Bevacizumab is a widely used oncology drug with peak global sales reaching approximately $7 billion, highlighting its significance in cancer treatment [2] - The collaboration between the company and Dongyao Pharmaceutical has led to efficient registration processes across various countries, with multiple GMP certifications obtained, showcasing the company's commitment to quality [3][4] Market Strategy - The company is focusing on deepening its presence in the Latin American market, which has shown a growth rate of 11.4% in pharmaceutical exports from China, making it a key area for expansion [3][4] - Colombia, as the fourth largest pharmaceutical market in Latin America, presents significant opportunities due to its reliance on imported biopharmaceuticals and strict regulatory standards, which enhances the credibility of the company's products [4] - The company aims to leverage its successful registration in Colombia to facilitate further market penetration in other Latin American countries [4] Internationalization Efforts - The company has developed a comprehensive "platform export" model that includes collaborative research, marketing, and localized sales strategies, enhancing its internationalization capabilities [5][6] - The transition from a focus on emerging markets to a more integrated approach that includes both the EU and emerging markets marks a significant evolution in the company's export strategy [6] - The recent approval of Bevacizumab in Colombia underscores the company's competitive advantages in overseas commercialization, positioning it for greater influence in the global pharmaceutical market [5][6]